IQVIA (IQV)
Combines healthcare intelligence and commercial technology with global clinical research services.
Something off on this page? Send us feedback.
Provides healthcare data, analytics, cloud software, consulting, contract sales, and patient engagement through Commercial Solutions, while Research & Development Solutions manages clinical trials, laboratories, regulatory support, and real-world research. Revenue is weighted toward outsourced R&D, with operations spanning the Americas, Europe and Africa, and Asia-Pacific.
Runs complementary Commercial Solutions and Research & Development Solutions businesses for life-sciences and healthcare clients. Commercial Solutions sells healthcare information, advanced analytics, cloud software, consulting, contract sales, and patient-engagement services. Research & Development Solutions manages outsourced clinical development, including study design, site start-up, patient recruitment, monitoring, regulatory support, laboratories, and real-world research.
Combines proprietary health datasets with technology and therapeutic expertise to inform commercial decisions and make trial planning and recruitment more targeted. Subscription information and cloud software sit alongside project-based research and outsourced engagement services, linking data products with execution across the drug lifecycle.
Serves clients in the Americas, Europe and Africa, and Asia-Pacific. Operations span more than 100 countries and depend on privacy-compliant access to health data and adherence to clinical-trial and healthcare regulations across jurisdictions.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $200 | Target: $270 |
| Jul 29, 2026 | RBC Capital | Reiterate | Rating: —Target: $270 | Target: $247 |
| Jul 29, 2026 | BMO Capital | Reiterate | Rating: —Target: $250 | Target: $270 |
| Jul 29, 2026 | Robert W. Baird | Target | Target: $249 | Target: $287 |
| Jul 13, 2026 | Mizuho Securities | Target | Target: $215 | Target: $230 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.08B · Total debt $16.24B · Total assets $29.88B · Shareholders' equity $6.17B
- Revenue
- $4.37B
- Operating income
- $506.0M
- Net income
- $256.0M
No dividends on record.
| Institutions | 93.24% | 158.23M shares | |
|---|---|---|---|
| 1,121 holders · as of Jun 30, 2026 | |||
| Insiders | 0.62% | 1.05M shares | |
| 14 holders · as of Sep 4, 2026 | |||
| Strategic holders | 14.30% | 24.27M shares | |
| 2 holders · as of Aug 15, 2024 | |||
| Adds to | 108.16% | ||
169.70M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 108.16%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Strategic | 8.92% | 15.14M | filed Feb 7, 2022 |
BlackRock, Inc.Institution | 8.57% | 14.55M | as of Jun 30, 2026 |
Harris Associates L PInstitution | 7.18% | 12.18M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.43% | 10.91M | as of Jun 30, 2026 |
GIC Private LtdStrategic | 5.38% | 9.13M | filed Aug 15, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | James G. Berkshire | officer: See Remarks | −2,668 | $261.33 |
| Jul 31, 2026 | Bhavik Patel | officer: See Remarks | −1,855 | $235.27 |
| Aug 3, 2026 | W. Richard Staub | officer: See Remarks | −5,500 | $232.68 |
| Jul 29, 2026 | Ari Bousbib | director, officer: See Remarks | −106,279 | $245.51 |
| Jul 29, 2026 | Keriann Cherofsky | officer: See Remarks | −558 | $245.21 |
- ICON
Largest pure-play CRO rival; head-to-head in global Phase I–IV trial services.
- Thermo Fisher Scientific
PPD division competes head-to-head in global Phase I–IV clinical research.
- Veeva Systems
Life sciences SaaS leader challenging IQVIA's commercial CRM and clinical data.
- Medpace
Fast-growing mid-tier CRO; wins small biotech mandates via full-service depth.
- Charles River Laboratories
Premier preclinical CRO; discovery and safety assessment overlap with IQVIA.
- Fortrea
Mid-tier CRO spun from Labcorp; Phase I–IV in oncology and rare disease.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IQVIA | $272.35 | +0.84% | $44.46B | 33.5 | 20.0 | 2.6 | +8.7% |
| ICON | $167.03 | −0.05% | $12.80B | 39.2 | 15.0 | 1.6 | +2.3% |
| Thermo Fisher Scientific | $659.46 | +0.14% | $243.49B | 35.4 | 25.1 | 5.3 | +10.5% |
| Veeva Systems | $270.30 | +3.60% | $42.38B | 42.9 | 28.0 | 12.3 | +17.6% |
| Medpace | $633.65 | +0.55% | $17.59B | 36.9 | 34.4 | 6.3 | +17.2% |
| Charles River Laboratories | $288.46 | +1.17% | $13.73B | — | 23.4 | 3.4 | −2.7% |
| Fortrea | $20.26 | −0.86% | $1.94B | — | 21.0 | 0.7 | −4.5% |
| Median | 38.1 | 24.3 | 4.3 | +6.4% |